|View printer-friendly version|
|February 22, 2005 10:13 a.m.|
|Teva and Lundbeck Announce European Approval for AZILECT® (rasagiline) 1mg for Parkinson's Disease|
Approved for use as monotherapy in early disease and adjunct therapy in moderate to advanced stages
Jerusalem, Israel and Copenhagen, Denmark, February 22, 2005 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and H. Lundbeck A/S announced today that the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product AZILECT® (rasagiline 1mg, once daily), for the treatment of Parkinson's disease (PD) both as monotherapy in patients with early PD and as adjunct treatment in moderate to advanced disease. The companies intend to market the product in various countries across Europe during the second quarter 2005.